Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations
Year: 2026
Type: article
Abstract: These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non-immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4-6 weeks post-reaction; whereas beyond 6 months, false-negative results increase. For chemotherapy-related reactions, earlier testing (within 2 weeks) remains necessary due to treatment urgency. The previously published multicenter ENDA study established the international reference method for positive immediate intradermal test reading: injection of exactly 0.02 mL with a wheal at 20 min measuring ≥ initial wheal +3 mm, representing a major standardization achievement. For patch testing, exact active ingredient concentrations must be systematically documented. When tablets are crushed and diluted at 30% in petrolatum, significant variability in final concentrations has been observed. The guidelines present validated nonirritant concentrations for major drug classes including antibiotics, contrast media, anesthetics, proton pump inhibitors, chemotherapies, and biologicals. Specific recommendations are based on negative controls demonstrating specificity, while conditional recommendations are provided when few or no negative controls are available. Risk stratification algorithms now allow direct drug provocation testing for mild maculopapular exanthema, bypassing preliminary skin tests. However, more severe reactions such as anaphylaxis require skin testing before considering drug provocation tests. For DRESS/AGEP/SJS/TEN, skin tests are useful and safe for identifying culprit drugs. These harmonized methods enable safe drug allergy delabeling while preserving diagnostic accuracy and patient safety. Strict adherence to these standardized protocols is essential to ensure reproducible results and safe clinical practice in drug hypersensitivity evaluation.
Source: Allergy
DOI: 10.1111/all.70466
Institutions: Inserm, Sorbonne Université, Institut Pierre Louis d‘Épidémiologie et de Santé Publique, Hôpital Tenon, University of Copenhagen, Copenhagen University Hospital, Gentofte Hospital, Murdoch University, Vanderbilt University Medical Center, University Hospital Southampton NHS Foundation Trust, University of Southampton, Ankara University, Ospedale San Bortolo, University Hospital of Geneva, McGill University Health Centre, Research Institute of the McGill University Health Centre, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Hospital Central de la Cruz Roja San José y Santa Adela, Universidad Alfonso X el Sabio, St Bartholomew's Hospital, Barts Health NHS Trust, Meyer Children's Hospital, University of Antwerp, Antwerp University Hospital, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, Technical University of Munich
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,300
Award: G2047066354
OpenAlex ID: W7203795000